DDInter1347 DDInter1763
Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts the option of single-dose administration and has been proven as non-inferior to a full course of [vancomycin] therapy.[A39384,A193482,L8492] On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion. Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion and contains a lower dose of 400 mg. Marketed by Melinta Therapeutics, Kimyrsa offers effective and time-efficient treatment for skin and skin structure infections.
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Oritavancin {u} (Compound) causes {v} (Side Effect) Musculoskeletal discomfort
Musculoskeletal discomfort {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Oritavancin {u} (Compound) causes {v} (Side Effect) Musculoskeletal discomfort
Musculoskeletal discomfort {u} (Side Effect) is caused by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Oritavancin {u} (Compound) resembles {v} (Compound) Telavancin
Telavancin {u} (Compound) causes {v} (Side Effect) Rash
Rash {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Oritavancin {u} (Compound) resembles {v} (Compound) Telavancin
Telavancin {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Oritavancin {u} (Compound) resembles {v} (Compound) Vancomycin
Vancomycin {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Oritavancin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Bortezomib {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Oritavancin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Warfarin
Warfarin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Oritavancin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Brigatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Oritavancin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Bortezomib {u} (Compound) downregulates {v} (Gene) PIGV
PIGV {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Oritavancin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Bortezomib {u} (Compound) upregulates {v} (Gene) SNX13
SNX13 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Oritavancin (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal discomfort (Side Effect) is caused by Temsirolimus (Compound)
Oritavancin (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal discomfort (Side Effect) is caused by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Oritavancin (Compound) resembles Telavancin (Compound) and Telavancin (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Temsirolimus (Compound)
Oritavancin (Compound) resembles Telavancin (Compound) and Telavancin may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Oritavancin (Compound) resembles Vancomycin (Compound) and Vancomycin may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Oritavancin may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Temsirolimus (Compound)
Oritavancin may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Oritavancin may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Oritavancin may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib (Compound) downregulates PIGV (Gene) and PIGV (Gene) is upregulated by Temsirolimus (Compound)
Oritavancin may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib (Compound) upregulates SNX13 (Gene) and SNX13 (Gene) is upregulated by Temsirolimus (Compound)